The U.S. Food and Drug Administration (USFDA) has granted Orphan Drug Designation to Phenobarbital for the treatment of patients with neonatal seizures.
The Orphan Drug Act provides economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the United States. Orphan Drug Designation will grant seven years of US market exclusivity upon approval of Phenobarbital for the treatment of patients with neonatal seizures. Incentives include waiver of user fee by USFDA and assistance in clinical trial design by USFDA.
Shares of SUN PHARMA ADVANCED RESEARCH COMPANY LTD. was last trading in BSE at Rs.122.65 as compared to the previous close of Rs. 121.05. The total number of shares traded during the day was 84295 in over 1444 trades.
The stock hit an intraday high of Rs. 125.6 and intraday low of 121.55. The net turnover during the day was Rs. 10365281.